ABPI: “Patients can’t afford to wait” for AMR infections research
The Association of the British Pharmaceutical Industry (ABPI) has responded to the Government's announcement of further details for how it will support pharmaceutical companies’...
SMC approves Ibrance for use within NHS Scotland
Pfizer has announced that the Scottish Medicines Consortium (SMC) has accepted Ibrance (palbociclib) for use within NHS Scotland for the treatment of hormone receptor...
Gene silencing therapy for hereditary amyloidosis approved by NICE
NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis. RNA interference (RNAi) therapeutics company, Alnylam UK Limited has welcomed a decision from the...
SMC recommends Darzalex as second-line treatment for multiple myeloma
The Scottish Medicines Consortium (SMC) has recommended Darzalex® (daratumumab) plus bortezomib and dexamethasone as an option for treating relapsed multiple myeloma in people who...
Wasdell Group’s EU HQ commences operations
Outsourcing partner for the pharmaceutical industry, The Wasdell Group (Wasdell), has announced that its new state-of-the-art facility in Dundalk, Ireland has received its Manufacturer’s...
AstraZeneca to appeal NICE’s osimertinib decision
AstraZeneca to appeal NICE's osimertinib decision following it not being recommended for use within NHS England. AstraZeneca will appeal a decision by the National Institute...
ABPI Chief Executive announces retirement
The ABPI Chief Executive Mike Thompson, has announced that he is due to retire at the end of 2019. Mike joined the ABPI in March...
Vizimpro recommended on NHS for NSCLC – NICE
Life-extending lung cancer treatment, Vizimpro recommended on NHS as a first-line treatment for non-small-cell lung cancer. Dacomitinib (Vizimpro, Pfizer) has been recommended as a first-line...
LEO Pharma takes walk in aid of National Eczema Society
27 colleagues from LEO Pharma are taking on the challenge of walking a marathon (26.2 miles) along the Thames Path, from Henley to Windsor,...
Cemiplimab recommended in Cancer Drugs Fund
Cemiplimab recommended in the Cancer Drugs Fund following draft guidance from the National Institute for Health and Care Excellence (NICE). NICE has issued draft guidance...
Latest articles
NICE approves ribociclib with fulvestrant for breast cancer
Patients to have a further drug combination option on Cancer Drugs Fund as NICE approves ribociclib with fulvestrant for breast cancer in draft guidance.
The positive...
New research highlights the relationship between sleep medication and dementia
New research presented at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles highlights the relationship between sleep medication and dementia. It examines the...
ViiV Healthcare to showcase innovation in HIV science
ViiV Healthcare has announced that 20 abstracts from its portfolio of late-stage pipeline and authorised HIV treatments will be presented at the 10th International...
Popular articles
ViiV Healthcare to showcase innovation in HIV science
ViiV Healthcare has announced that 20 abstracts from its portfolio of late-stage pipeline and authorised HIV treatments will be presented at the 10th International...
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Driving patient centricity in patient-facing programmes
How one company created a core proposition which puts the patient first in all the work it does. All companies within the healthcare sector...
New research highlights the relationship between sleep medication and dementia
New research presented at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles highlights the relationship between sleep medication and dementia. It examines the...
Engaging patients earlier in clinical development
Successful patient engagement is essential to the clinical development process. How can companies get it right? Patient and public engagement in clinical research means that...